FADY I MALIK

Summary

Affiliation: Cytokinetics Inc
Country: USA

Publications

  1. pmc Activation of fast skeletal muscle troponin as a potential therapeutic approach for treating neuromuscular diseases
    Alan J Russell
    Preclinical Research and Development, San Francisco, California, USA
    Nat Med 18:452-5. 2012
  2. pmc Cardiac myosin activation: a potential therapeutic approach for systolic heart failure
    FADY I MALIK
    Preclinical Research and Development, Cytokinetics, Inc, South San Francisco, CA 94080, USA
    Science 331:1439-43. 2011
  3. doi request reprint Cardiac myosin activation part 1: from concept to clinic
    FADY I MALIK
    Preclinical Research and Development, Cytokinetics, Inc, South San Francisco, CA 94080, USA
    J Mol Cell Cardiol 51:454-61. 2011
  4. pmc Fast skeletal muscle troponin activator tirasemtiv increases muscle function and performance in the B6SJL-SOD1G93A ALS mouse model
    Darren T Hwee
    Cytokinetics, Inc, South San Francisco, California, United States of America
    PLoS ONE 9:e96921. 2014
  5. doi request reprint Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study
    John R Teerlink
    Section of Cardiology, San Francisco Veterans Affairs Medical Center, University of California, San Francisco, CA 94121 1545, USA
    Lancet 378:667-75. 2011
  6. ncbi request reprint Improvement of cardiac function by a cardiac Myosin activator in conscious dogs with systolic heart failure
    You Tang Shen
    CV Dynamics, Inc, North Brunswick, NJ, USA
    Circ Heart Fail 3:522-7. 2010
  7. ncbi request reprint Novel drug mechanisms in development for heart failure
    Soidjon D Khodjaev
    Section of Cardiology, San Francisco Veterans Affairs Medical Center, 111C, 4150 Clement Street, San Francisco, CA, 94121 1545, USA
    Pflugers Arch 466:1219-25. 2014

Collaborators

  • John R Teerlink
  • You Tang Shen
  • Xin Zhao
  • David Clarke
  • Dennis R Claflin
  • Christophe Depre
  • Alan J Russell
  • Darren T Hwee
  • Soidjon D Khodjaev
  • Aaron C Hinken
  • Zhiheng Jia
  • David J Morgans
  • Adam Kennedy
  • Jeffrey R Jasper
  • Julie Ryans
  • Marc Garard
  • Scott E Collibee
  • Kenneth H Lee
  • Guillermo Godinez
  • Alexander R Muci
  • Hector Rodriguez
  • Michael M Chen
  • Vipin Vijayakumar
  • Daniel L Albertus
  • Khalil G Saikali
  • William F Browne
  • Richard Hansen
  • James J Hartman
  • Bradley P Morgan
  • Julia Schaletzky
  • DAVID MARQUEZ
  • Pu Ping Lu
  • Lena Driscoll
  • Raja Kawas

Detail Information

Publications7

  1. pmc Activation of fast skeletal muscle troponin as a potential therapeutic approach for treating neuromuscular diseases
    Alan J Russell
    Preclinical Research and Development, San Francisco, California, USA
    Nat Med 18:452-5. 2012
    ..Troponin activation may provide a new therapeutic approach to improve physical activity in diseases where neuromuscular function is compromised...
  2. pmc Cardiac myosin activation: a potential therapeutic approach for systolic heart failure
    FADY I MALIK
    Preclinical Research and Development, Cytokinetics, Inc, South San Francisco, CA 94080, USA
    Science 331:1439-43. 2011
    ..Cardiac myosin activation may provide a new therapeutic approach for systolic heart failure...
  3. doi request reprint Cardiac myosin activation part 1: from concept to clinic
    FADY I MALIK
    Preclinical Research and Development, Cytokinetics, Inc, South San Francisco, CA 94080, USA
    J Mol Cell Cardiol 51:454-61. 2011
    ..Cardiac myosin activation may provide a new therapeutic approach for systolic heart failure. This article is part of a special issue entitled "Key Signaling Molecules in Hypertrophy and Heart Failure."..
  4. pmc Fast skeletal muscle troponin activator tirasemtiv increases muscle function and performance in the B6SJL-SOD1G93A ALS mouse model
    Darren T Hwee
    Cytokinetics, Inc, South San Francisco, California, United States of America
    PLoS ONE 9:e96921. 2014
    ..These results support the potential of fast skeletal troponin activators to improve muscle function in neuromuscular diseases...
  5. doi request reprint Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study
    John R Teerlink
    Section of Cardiology, San Francisco Veterans Affairs Medical Center, University of California, San Francisco, CA 94121 1545, USA
    Lancet 378:667-75. 2011
    ..This study tested the hypothesis that omecamtiv mecarbil, a selective cardiac myosin activator, will augment cardiac function in human beings...
  6. ncbi request reprint Improvement of cardiac function by a cardiac Myosin activator in conscious dogs with systolic heart failure
    You Tang Shen
    CV Dynamics, Inc, North Brunswick, NJ, USA
    Circ Heart Fail 3:522-7. 2010
    ..In this investigation, we examined the effects of a novel cardiac myosin activator, omecamtiv mecarbil (formerly CK-1827452) in 2 different models of heart failure...
  7. ncbi request reprint Novel drug mechanisms in development for heart failure
    Soidjon D Khodjaev
    Section of Cardiology, San Francisco Veterans Affairs Medical Center, 111C, 4150 Clement Street, San Francisco, CA, 94121 1545, USA
    Pflugers Arch 466:1219-25. 2014
    ....